Cargando…

Vandetanib (ZD6474) induces antiangiogenesis through mTOR–HIF-1 alpha–VEGF signaling axis in breast cancer cells

OBJECTIVE: Vandetanib, also known as ZD6474, has recently been proved to be a clinical drug for cancer by targeting vascular endothelial growth factor receptor 2 (VEGFR2), EGFR, and RET tyrosine kinases. We hypothesized that vandetanib will be a drug candidate for breast cancer treatment by targetin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Ling, Yu, Jingkui, Jiao, Shuhong, Wang, Wei, Zhang, Fen, Sun, Shiqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278704/ https://www.ncbi.nlm.nih.gov/pubmed/30555244 http://dx.doi.org/10.2147/OTT.S175578

Ejemplares similares

Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer
por: Deshpande, Hari, et al.
Publicado: (2011)

Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer
por: Flanigan, Jaclyn, et al.
Publicado: (2010)

Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma
por: Yoshikawa, D, et al.
Publicado: (2009)

ZD6474 – clinical experience to date
por: Heymach, J V
Publicado: (2005)

Vandetanib (Zactima, ZD6474) Antagonizes ABCC1- and ABCG2-Mediated Multidrug Resistance by Inhibition of Their Transport Function
por: Zheng, Li-sheng, et al.
Publicado: (2009)

Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer
por: Meyerhardt, Jeffrey A., et al.
Publicado: (2012)

Autophagy inhibition induces enhanced proapoptotic effects of ZD6474 in glioblastoma
por: Shen, J, et al.
Publicado: (2013)

ZD6474 attenuates TGF-β1-induced fibrosis in human Tenon fibroblasts and inhibits neovascularization via AKT-mTOR signaling pathway
por: Liu, Wenting, et al.
Publicado: (2022)

ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein
por: Freshney, R I
Publicado: (2007)

ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein
por: Mi, Y, et al.
Publicado: (2007)

ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
por: Ryan, A J, et al.
Publicado: (2005)

Reply: ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein
por: Mi, Y, et al.
Publicado: (2007)

The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model
por: Sandström, M, et al.
Publicado: (2004)

ZD6474 in combination with paclitaxel and UVB irradiation enhances the antiproliferative effect and apoptosis on breast carcinoma
por: Sarkar, S, et al.
Publicado: (2009)

Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours
por: Checkley, D, et al.
Publicado: (2003)

ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib
por: Liu, Jiani, et al.
Publicado: (2015)

Targeted therapy against EGFR and VEGFR using ZD6474 enhances the therapeutic potential of UV-B phototherapy in breast cancer cells
por: Sarkar, Siddik, et al.
Publicado: (2013)

Intravoxel Incoherent Motion Diffusion-weighted Magnetic Resonance Imaging for Monitoring the Early Response to ZD6474 from Nasopharyngeal Carcinoma in Nude Mouse
por: Cui, Yanfen, et al.
Publicado: (2015)

Hypertension and Antiangiogenesis: The Janus Face of VEGF Inhibitors
por: Touyz, Rhian M., et al.
Publicado: (2019)

Lymphangiogenesis in Gastric Cancer regulated through Akt/mTOR-VEGF-C/VEGF-D axis
por: Chen, Hongxia, et al.
Publicado: (2015)

Vandetanib
por: Vozniak, J. Michael, et al.
Publicado: (2012)

HIF-1α increases the osteogenic capacity of ADSCs by coupling angiogenesis and osteogenesis via the HIF-1α/VEGF/AKT/mTOR signaling pathway
por: Song, Shuang, et al.
Publicado: (2023)

Inhibition of Protein Kinase C Delta Attenuates Allergic Airway Inflammation through Suppression of PI3K/Akt/mTOR/HIF-1 Alpha/VEGF Pathway
por: Choi, Yun Ho, et al.
Publicado: (2013)

Synchronous inhibition of mTOR and VEGF/NRP1 axis impedes tumor growth and metastasis in renal cancer
por: Pal, Krishnendu, et al.
Publicado: (2019)

VEGF-mTOR signaling links obesity and endometrial cancer
por: Sahoo, Subhransu S., et al.
Publicado: (2018)

mTOR Directs Breast Morphogenesis through the PKC-alpha-Rac1 Signaling Axis
por: Morrison, Meghan M., et al.
Publicado: (2015)

Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF
por: Im, S-A, et al.
Publicado: (2001)

Amplification of the Angiogenic Signal through the Activation of the TSC/mTOR/HIF Axis by the KSHV vGPCR in Kaposi's Sarcoma
por: Jham, Bruno C., et al.
Publicado: (2011)

Characterization of the transcriptional and metabolic responses of pediatric high grade gliomas to mTOR-HIF-1α axis inhibition
por: Nguyen, Aurélia, et al.
Publicado: (2017)

STAT3 and mTOR: co-operating to drive HIF and angiogenesis
por: Dodd, Kayleigh M., et al.
Publicado: (2015)

HIF is not essential for suppression of experimental tumor growth by mTOR inhibition
por: Knaup, Karl X., et al.
Publicado: (2017)

Apoferritin/Vandetanib Association Is Long-Term Stable But Does Not Improve Pharmacological Properties of Vandetanib
por: Jáklová, Kateřina, et al.
Publicado: (2021)

The mTOR–Autophagy Axis and the Control of Metabolism
por: Deleyto-Seldas, Nerea, et al.
Publicado: (2021)

The mTOR–lysosome axis at the centre of ageing
por: Carosi, Julian M., et al.
Publicado: (2021)

Adiponectin promotes VEGF-A-dependent angiogenesis in human chondrosarcoma through PI3K, Akt, mTOR, and HIF-α pathway
por: Lee, Hsiang-Ping, et al.
Publicado: (2015)

miRNA-29 aggravates myocardial infarction via inhibiting the PI3K/mTOR/HIF1α/VEGF pathway
por: Wang, Xiaoxi, et al.
Publicado: (2022)

MicroRNA-200c affects bladder cancer angiogenesis by regulating the Akt2/mTOR/HIF-1 axis
por: Wu, Shui-Qing, et al.
Publicado: (2019)

PI3K/AKT/mTOR Dysregulation and Reprogramming Metabolic Pathways in Renal Cancer: Crosstalk with the VHL/HIF Axis
por: Badoiu, Silviu Constantin, et al.
Publicado: (2023)

Hypoxic Regulation of VEGF, HIF-1(alpha) in Coronary Collaterals Development
por: Sung, Ki Chul, et al.
Publicado: (2005)

Monitoring antiangiogenesis of bevacizumab in zebrafish
por: Zhang, Jing, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_oish2041ofmb93fshsaitiamka